Themis Medicare has updated the electronic contact details for its compliance officer and registrar to ensure seamless investor communication. The company informed the Bombay Stock Exchange and National Stock Exchange of India Limited on August 17, 2026, regarding the change in the Company Secretary’s registered email address.

The existing email ID for Sangameshwar Iyer has been replaced with a new address for Suresh Savaliya. All future correspondence regarding investor relations and compliance matters should be directed to the new ID. This administrative update ensures that regulatory filings and investor queries are routed correctly within the corporate governance framework.

Contact Details Update

The company also updated the email address for its Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited. Investors and stakeholders are advised to use the new RTA email ID for all share-related inquiries and documentation requests.

The notification was signed by Dinesh S. Patel, Chairman and Director of Themis Medicare Limited. The company’s corporate office is located in Goregaon, Mumbai, while its registered office remains in Vapi, Gujarat. These changes do not impact the company’s financial operations or strategic direction but serve to maintain accurate records with the exchanges.

Themis Medicare reported a significant turnaround in profitability for the first quarter of FY27, posting a standalone net profit of ₹287.4 lakh for the period ended June 30, 2026. This compares to a net loss of ₹153.7 lakh in the same quarter of the previous fiscal year. The consolidated net profit attributable to equity holders was ₹246.1 lakh, up from a loss of ₹142.2 lakh in Q1FY26.

The profit surge was not operational but stemmed from a one-time exceptional item. The company recorded a profit of ₹996.7 lakh (standalone) and ₹929.5 lakh (consolidated) following the sale of 2,497,190 equity shares in its associate, Gujarat Themis Biosyn Limited, for a consideration of ₹100 crore. Without this gain, the standalone operations incurred a loss before tax of ₹569.4 lakh.

Financial Performance

Revenue from operations declined during the quarter, reflecting softness in the core pharmaceutical business. Standalone revenue stood at ₹869.6 lakh, down 10.9% year-on-year from ₹975.8 lakh in Q1FY26. On a consolidated basis, revenue remained identical at ₹869.6 lakh.

Operating expenses increased significantly, with total expenses rising to ₹1,449.0 lakh in the standalone results, compared to ₹1,126.8 lakh in the prior year period. Other expenses specifically jumped to ₹592.1 lakh from ₹304.1 lakh year-on-year, contributing to the operational loss despite the revenue contraction being modest.

What the Numbers Show

The financial data reveals a stark divergence between operational performance and bottom-line results. While the company turned profitable on paper, the core business widened its operating loss. The standalone loss before exceptional items and tax expanded to ₹569.4 lakh from ₹139.2 lakh in Q1FY26. This indicates that the profit figure is entirely dependent on non-recurring capital gains rather than improvements in the pharmaceutical segment's efficiency or sales volume.

Key Managerial Personnel Changes

Alongside the financial results, the Board of Directors approved changes in key managerial personnel effective August 13, 2026. Mr. Nagraj Mogaveera resigned as Interim Company Secretary and Compliance Officer to transition into the role of Deputy Manager – Secretarial Department within the company.

Mr. Suresh Savaliya was appointed as the new Company Secretary, Compliance Officer, and Key Managerial Personnel. A qualified Company Secretary and member of the Institute of Company Secretaries of India (ICSI), Mr. Savaliya brings 23 years of post-qualification experience. He previously served with Reliance Industries Limited and the Essel Group, handling corporate governance, SEBI compliances, and board matters.

Auditor Review

Krishna & Co., Chartered Accountants, conducted the limited review of the unaudited standalone and consolidated financial results. The auditors stated that nothing came to their attention to cause them to believe the statements did not disclose the information required under Regulation 33 of the SEBI Listing Regulations or contained material misstatements. The audit report also highlighted the pending RBI approval for writing off investments in the struck-off UK subsidiary, Carpo Medicals Limited.